logo
  

Haemonetics Q4 Profit Falls, But Beats Estimates - Update

(Adds Outlook)

Looking ahead, for the full year, Haemonetics Corporation (HAE) expects to report adjusted income per share of $4.45 to $4.75, above the analysts' estimate of $4.4 per share.

Revenue is projected to grow 5 percent to 8 percent. Analysts, on average, expect the firm to generate revenue of $1.37 billion, for the year.

Q4 Results:

Haemonetics revealed earnings for fourth quarter that decreased from last year but beat the Street estimates.

The company's bottom line came in at $20.367 million, or $0.40 per share. This compares with $29.383 million, or $0.57 per share, in last year's fourth quarter.

Excluding items, Haemonetics Corp reported adjusted earnings of $46.016 million or $0.90 per share for the period.

Analysts on average had expected the company to earn $0.89 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.

The company's revenue for the quarter rose 12.8% to $343.290 million from $304.416 million last year.

Haemonetics Corp earnings at a glance (GAAP) :

-Earnings (Q4): $20.367 Mln. vs. $29.383 Mln. last year.
-EPS (Q4): $0.40 vs. $0.57 last year.
-Revenue (Q4): $343.290 Mln vs. $304.416 Mln last year.

For comments and feedback contact: editorial@rttnews.com

Business News

In this week's video, we highlight Roche's pioneering approach for weight loss and glucose control. Meanwhile, the EMA has taken strict action on certain preterm birth drugs and Bayer has downsized its staff. In a breakthrough for cancer treatment, the FDA has approved a groundbreaking T-cell engager therapy. Amid progress, setbacks emerge as another ALS drug study has faltered, following closely on the heels of Amylyx Pharma's recent decision to withdraw its FDA-approved ALS drug, Relyvrio.

View More Videos
Follow RTT